LONG-TERM ESTROGEN REPLACEMENT THERAPY PREVENTS BONE LOSS AND FRACTURES
LONG-TERM ESTROGEN REPLACEMENT THERAPY PREVENTS BONE LOSS AND FRACTURES
复制标题
DOI：
10.7326/0003-4819-102-3-319
复制
发表时间：
1985-01-01
影响因子：
39.2
通讯作者：
CANN, CE
中科院分区：
文献类型：
--
作者：
ETTINGER, B;GENANT, HK;CANN, CE
尽管一些病例对照研究显示绝经后雌激素的使用与骨折呈负相关，但骨折发生率的量化一直缺乏。为了量化雌激素替代疗法预防绝经后骨质疏松症的程度，我们进行了一项回顾性研究，比较了245名长期雌激素使用者和245名年龄匹配的对照组的骨折发生率，平均随访17.6年。对18名使用雌激素替代疗法的女性及其对照组（平均年龄73岁）进行了骨矿物质定量评估。雌激素使用者骨质疏松性骨折发生率是对照组的50% （P < 0.01）。雌激素使用者的骨矿物质含量显著增加：脊柱矿物质含量增加54.2% (P < 0.002)，前臂矿物质含量增加19.4% (P < 0.0005)，掌骨皮质厚度增加15.6% （P < 0.005）。长期雌激素替代疗法对骨质流失和骨折具有显著的保护作用。
Although several case-control studies have shown an inverse association between postmenopausal estrogen use and fractures, quantitation of fracture incidence has been lacking. To quantify the degree to which estrogen replacement therapy prevents postmenopausal osteoporosis, a retrospective study was done comparing the occurrence of fractures in 245 long-term estrogen users and 245 age-matched controls, followed for an average of 17.6 yr. Quantitative bone mineral assessments were obtained from 18 women using estrogen replacement therapy and their controls (average age, 73 yr). Osteoporotic fracture incidence in estrogen users was 50% as great as in the controls (P < 0.01). Estrogen users showed significantly greater bone mineral: 54.2% greater spinal mineral (P < 0.002), 19.4% greater forearm mineral (P < 0.0005), and 15.6% greater metacarpal cortical thickness (P < 0.005). Long-term estrogen replacement therapy confers significant protection against bone loss and fracture.